{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:23:12Z","timestamp":1792513392714,"version":"4.5.0"},"reference-count":72,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Volkswagen-Stiftung","award":["AZ-9B783-M.M.\/S.B.T."],"award-info":[{"award-number":["AZ-9B783-M.M.\/S.B.T."]}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GRK2504.1-2\/A1"],"award-info":[{"award-number":["GRK2504.1-2\/A1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["MA 1289\/11-3"],"award-info":[{"award-number":["MA 1289\/11-3"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["MA 1289\/17-1"],"award-info":[{"award-number":["MA 1289\/17-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"publisher","award":["AZ2022.073.1"],"award-info":[{"award-number":["AZ2022.073.1"]}],"id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002745","name":"Bayerische Forschungsstiftung","doi-asserted-by":"crossref","award":["DeeP-CMV\/AP-5\/M.M."],"award-info":[{"award-number":["DeeP-CMV\/AP-5\/M.M."]}],"id":[{"id":"10.13039\/501100002745","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background. To date, a number of human pathogenic viruses are still unaddressed by the current repertoire of approved antiviral drugs. In order to widen this spectrum of preventive measures against virus infections, we have focused on additional host targets that exert interesting virus-supportive functions. Inhibitors of cyclin-dependent kinase 8 (CDK8) have been found to exhibit highly pronounced and relatively broad antiviral activity. Objectives. The current research question concerning the potential for broad-spectrum antiviral drug activity should be addressed in detail to understand the mechanistic basis of the antiviral target function of CDK8. Materials and Methods. We established and specifically customized six assay systems, three of these newly developed for the present study, to corroborate the range of CDK8 inhibitors\u2019 antiviral activity against four \u03b1-, \u03b2-, and \u03b3-herpesviruses as well as two non-herpesviruses. Results. Similar to our earlier analysis of CDK7 and CDK9 inhibitors, the clinically relevant CDK8 inhibitors currently in use demonstrated antiherpesviral activity in cell-culture-based infection models. Interestingly, the antiviral efficacy against various human and animal cytomegaloviruses was particularly strong at nanomolar concentrations, whereas other herpesviruses or non-herpesviruses showed an intermediate or low sensitivity to CDK8 inhibitors. Thus, this approach provided novel insights into the inhibitory potential of the CDK8 inhibitors, such as CCT-251921, MSC-2530818, and BI-1347, when analyzed against equine herpesvirus 1 (EHV-1, \u03b1-herpesvirus), human herpesvirus 6A (HHV-6A, \u03b2), Epstein\u2013Barr virus (EBV, \u03b3), murine herpesvirus 68 (MHV-68, \u03b3), vaccinia virus (VV, non-herpes DNA virus), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, non-herpes RNA virus). Conclusions. Our results confirm that drug sensitivity to CDK8 inhibitors, on the one hand, is very strong for certain viruses and, on the other hand, varies widely within the spectrum of viruses and host cell types analyzed. This suggests that CDK8 may play several different roles in viral replication. The option of a refined CDK8-specific antiviral drug targeting is discussed.<\/jats:p>","DOI":"10.3390\/ph18101560","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T16:33:22Z","timestamp":1760632402000},"page":"1560","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["New Assay Systems to Characterize the Broad-Spectrum Antiherpesviral and Non-Herpesviral Activity of Cyclin-Dependent Kinase (CDK) 8 Inhibitors"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8984-0340","authenticated-orcid":false,"given":"Debora","family":"Obergf\u00e4ll","sequence":"first","affiliation":[{"name":"Harald zur Hausen Institute of Virology, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3011-8416","authenticated-orcid":false,"given":"Friedrich","family":"Hahn","sequence":"additional","affiliation":[{"name":"Harald zur Hausen Institute of Virology, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jintawee","family":"Kicuntod","sequence":"additional","affiliation":[{"name":"Harald zur Hausen Institute of Virology, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Wangen","sequence":"additional","affiliation":[{"name":"Harald zur Hausen Institute of Virology, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"K\u00f6gler","sequence":"additional","affiliation":[{"name":"Harald zur Hausen Institute of Virology, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Wagner","sequence":"additional","affiliation":[{"name":"Harald zur Hausen Institute of Virology, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1328-2695","authenticated-orcid":false,"given":"Benedikt","family":"Kaufer","sequence":"additional","affiliation":[{"name":"Institute of Virology, Freie Universit\u00e4t Berlin, 14163 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Marschall","sequence":"additional","affiliation":[{"name":"Harald zur Hausen Institute of Virology, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"ref_1","first-page":"45","article-title":"Primary Human Cytomegalovirus (HCMV) Infection in Pregnancy","volume":"114","author":"Buxmann","year":"2017","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Chen, S.J., Wang, S.C., and Chen, Y.C. (2022). Challenges, Recent Advances and Perspectives in the Treatment of Human Cytomegalovirus Infections. Trop. Med. Infect. Dis., 7.","DOI":"10.3390\/tropicalmed7120439"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.antiviral.2018.07.013","article-title":"Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus","volume":"157","author":"Chou","year":"2018","journal-title":"Antivir. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41579-021-00582-z","article-title":"Pathogenesis of human cytomegalovirus in the immunocompromised host","volume":"19","author":"Griffiths","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Gugliesi, F., Coscia, A., Griffante, G., Galitska, G., Pasquero, S., Albano, C., and Biolatti, M. (2020). Where do we Stand after Decades of Studying Human Cytomegalovirus?. Microorganisms, 8.","DOI":"10.3390\/microorganisms8050685"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1741-4520.2009.00222.x","article-title":"Effects of cytomegalovirus infection on embryogenesis and brain development","volume":"49","author":"Tsutsui","year":"2009","journal-title":"Congenit. Anom."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"8103","DOI":"10.1002\/chem.201800729","article-title":"Synthesis of Artemisinin-Derived Dimers, Trimers and Dendrimers: Investigation of Their Antimalarial and Antiviral Activities Including Putative Mechanisms of Action","volume":"24","author":"Hahn","year":"2018","journal-title":"Chemistry"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"104639","DOI":"10.1016\/j.antiviral.2019.104639","article-title":"Artemisone demonstrates synergistic antiviral activity in combination with approved and experimental drugs active against human cytomegalovirus","volume":"172","author":"Laskov","year":"2019","journal-title":"Antivir. Res."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Wild, M., Hahn, F., Grau, B., Herrmann, L., Niesar, A., Sch\u00fctz, M., Lorion, M.M., Ackermann, L., Tsogoeva, S.B., and Marschall, M. (2020). The Artemisinin-Derived Autofluorescent Compound BG95 Exerts Strong Anticytomegaloviral Activity Based on a Mitochondrial Targeting Mechanism. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21155578"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Wild, M., Karner, D., Eickhoff, J., Wagner, S., Kicuntod, J., Chang, W., Barry, P., Jonjic, S., Lenac Rovis, T., and Marschall, M. (2023). Combined Treatment with Host-Directed and Anticytomegaloviral Kinase Inhibitors: Mechanisms, Synergisms and Drug Resistance Barriers. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15122680"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Wild, M., Kicuntod, J., Seyler, L., Wangen, C., Bertzbach, L.D., Conradie, A.M., Kaufer, B.B., Wagner, S., Michel, D., and Eickhoff, J. (2021). Combinatorial Drug Treatments Reveal Promising Anticytomegaloviral Profiles for Clinically Relevant Pharmaceutical Kinase Inhibitors (PKIs). Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020575"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Bachman, L.O., and Zwezdaryk, K.J. (2023). Targeting the Host Mitochondria as a Novel Human Cytomegalovirus Antiviral Strategy. Viruses, 15.","DOI":"10.3390\/v15051083"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Bogner, E., Egorova, A., and Makarov, V. (2021). Small Molecules-Prospective Novel HCMV Inhibitors. Viruses, 13.","DOI":"10.3390\/v13030474"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/bmb\/ldz031","article-title":"Advances in the treatment of cytomegalovirus","volume":"131","author":"Krishna","year":"2019","journal-title":"Br. Med. Bull."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2146\/ajhp080206","article-title":"Maraviroc: A coreceptor CCR5 antagonist for management of HIV infection","volume":"66","author":"Yost","year":"2009","journal-title":"Am. J. Health-Syst. Pharm."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"De Luca, A., Pezzotti, P., Boucher, C., D\u00f6ring, M., Incardona, F.A.-O., Kaiser, R., Lengauer, T., Pfeifer, N., Sch\u00fclter, E., and Vandamme, A.M. (2019). Clinical use, efficacy, and durability of maraviroc for antiretroviral therapy in routine care: A European survey. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0225381"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/135965350901400514","article-title":"Maraviroc: Pharmacokinetics and drug interactions","volume":"14","author":"Abel","year":"2024","journal-title":"Antivir. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4254\/wjh.v8.i2.123","article-title":"Ribavirin: Past, present and future","volume":"8","author":"Jacques","year":"2016","journal-title":"World J. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s00109-001-0308-0","article-title":"Ribavirin\u2019s antiviral mechanism of action: Lethal mutagenesis?","volume":"80","author":"Crotty","year":"2022","journal-title":"J. Mol. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/liv.13212","article-title":"Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection","volume":"37","author":"Feld","year":"2017","journal-title":"Liver Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"104247","DOI":"10.1016\/j.jcv.2019.104247","article-title":"Antiviral activity of ribavirin and favipiravir against human astroviruses","volume":"123","author":"Janowski","year":"2020","journal-title":"J. Clin. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1007\/s00018-005-5455-y","article-title":"The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus","volume":"63","author":"Dixit","year":"2006","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1517\/14656566.2.8.1317","article-title":"Ribavirin--current status of a broad spectrum antiviral agent","volume":"2","author":"Snell","year":"2001","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/jvh.13811","article-title":"Bulevirtide-based treatment strategies for chronic hepatitis delta: A review","volume":"30","author":"Degasperi","year":"2023","journal-title":"J. Viral. Hepat."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s40265-020-01400-1","article-title":"Bulevirtide: First Approval","volume":"80","author":"Kang","year":"2020","journal-title":"Drugs"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa2213429","article-title":"A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D","volume":"389","author":"Wedemeyer","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1473-3099(22)00318-8","article-title":"Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): A multicentre, randomised, parallel-group, open-label, phase 2 trial","volume":"23","author":"Wedemeyer","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"100686","DOI":"10.1016\/j.jhepr.2023.100686","article-title":"Treating hepatitis D with bulevirtide\u2014Real-world experience from 114 patients","volume":"5","author":"Tacke","year":"2023","journal-title":"JHEP Rep."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Brillanti, S. (2022). Management of Delta Hepatitis 45 Years after the Discovery of HDV. J. Clin. Med., 11.","DOI":"10.3390\/jcm11061587"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/B978-0-12-385987-7.00004-X","article-title":"Regulatory roles of protein kinases in cytomegalovirus replication","volume":"80","author":"Marschall","year":"2011","journal-title":"Adv. Virus Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/cid\/ciab988","article-title":"Maribavir for Refractory Cytomegalovirus Infections with or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial","volume":"75","author":"Avery","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMoa1714656","article-title":"Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation","volume":"381","author":"Maertens","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Marschall, M., Sch\u00fctz, M., Wild, M., Socher, E., Wangen, C., Dhotre, K., Rawlinson, W.D., and Sticht, H. (2024). Understanding the Cytomegalovirus Cyclin-Dependent Kinase Ortholog pUL97 as a Multifaceted Regulator and an Antiviral Drug Target. Cells, 13.","DOI":"10.3390\/cells13161338"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.antiviral.2015.10.003","article-title":"The broad-spectrum antiinfective drug artesunate interferes with the canonical nuclear factor kappa B (NF-kappaB) pathway by targeting RelA\/p65","volume":"124","author":"Hutterer","year":"2015","journal-title":"Antivir. Res."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Obergf\u00e4ll, D., Wild, M., Sommerer, M., Barillas Dahm, M., Kicuntod, J., Tillmanns, J., K\u00f6gler, M., L\u00f6sing, J., Dhotre, K., and M\u00fcller, R. (2024). Cyclin-Dependent Kinase 8 Represents a Positive Regulator of Cytomegalovirus Replication and a Novel Host Target for Antiviral Strategies. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16091238"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"8605","DOI":"10.1074\/jbc.M805693200","article-title":"Cyclin-dependent Kinases Phosphorylate the Cytomegalovirus RNA Export Protein pUL69 and Modulate Its Nuclear Localization and Activity","volume":"284","author":"Rechter","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1586\/14787210.4.6.953","article-title":"First demonstration of the effectiveness of inhibitors of cellular protein kinases in antiviral therapy","volume":"4","author":"Schang","year":"2006","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Wild, M., Hahn, F., Bruckner, N., Sch\u00fctz, M., Wangen, C., Wagner, S., Sommerer, M., Strobl, S., and Marschall, M. (2022). Cyclin-Dependent Kinases (CDKs) and the Human Cytomegalovirus-Encoded CDK Ortholog pUL97 Represent Highly Attractive Targets for Synergistic Drug Combinations. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23052493"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1126\/science.1152095","article-title":"Phosphorylation of Retinoblastoma Protein by Viral Protein with Cyclin-Dependent Kinase Function","volume":"320","author":"Hume","year":"2008","journal-title":"Science"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Kuny, C.V., Chinchilla, K., Culbertson, M.R., and Kalejta, R.F. (2010). Cyclin-dependent kinase-like function is shared by the beta- and gamma- subset of the conserved herpesvirus protein kinases. PLoS Pathog., 6.","DOI":"10.1371\/journal.ppat.1001092"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1099\/vir.0.030494-0","article-title":"Recruitment of cyclin-dependent kinase 9 to nuclear compartments during cytomegalovirus late replication: Importance of an interaction between viral pUL69 and cyclin T1","volume":"92","author":"Feichtinger","year":"2011","journal-title":"J. Gen. Virol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Hahn, F., Hamilton, S.T., Wangen, C., Wild, M., Kicuntod, J., Bruckner, N., Follett, J.E.L., Herrmann, L., Kheimar, A., and Kaufer, B.B. (2021). Development of a PROTAC-Based Targeting Strategy Provides a Mechanistically Unique Mode of Anti-Cytomegalovirus Activity. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222312858"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1128\/AAC.04534-14","article-title":"A novel CDK7 inhibitor of the Pyrazolotriazine class exerts broad-spectrum antiviral activity at nanomolar concentrations","volume":"59","author":"Hutterer","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1128\/MCB.00595-14","article-title":"Cyclin-dependent kinase 7 controls mRNA synthesis by affecting stability of preinitiation complexes, leading to altered gene expression, cell cycle progression, and survival of tumor cells","volume":"34","author":"Kelso","year":"2014","journal-title":"Mol. Cell. Biol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Kicuntod, J., H\u00e4ge, S., Hahn, F., Sticht, H., and Marschall, M. (2022). The Oligomeric Assemblies of Cytomegalovirus Core Nuclear Egress Proteins Are Associated with Host Kinases and Show Sensitivity to Antiviral Kinase Inhibitors. Viruses, 14.","DOI":"10.3390\/v14051021"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Rovnak, J., and Quackenbush, S.L. (2022). Exploitation of the Mediator complex by viruses. PLoS Pathog., 18.","DOI":"10.1371\/journal.ppat.1010422"},{"key":"ref_47","first-page":"157","article-title":"Cellular proteins (cyclin dependent kinases) as potential targets for antiviral drugs","volume":"12","author":"Schang","year":"2001","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Yu, D., Wagner, S., Sch\u00fctz, M., Jeon, Y., Seo, M., Kim, J., Bruckner, N., Kicuntod, J., Tillmanns, J., and Wangen, C. (2024). An Antiherpesviral Host-Directed Strategy Based on CDK7 Covalently Binding Drugs: Target-Selective, Picomolar-Dose, Cross-Virus Reactivity. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16020158"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/35024111","article-title":"TFIIH is negatively regulated by cdk8-containing mediator complexes","volume":"407","author":"Akoulitchev","year":"2000","journal-title":"Nature"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Rice, S., Kim, S.M., Rodriguez, C., Songock, W., Raikhy, G., Lopez, R., Henderson, L., Yusufji, A., and Bodily, J. (2020). Suppression of a Subset of Interferon-Induced Genes by Human Papillomavirus Type 16 E7 via a Cyclin Dependent Kinase 8-Dependent Mechanism. Viruses, 12.","DOI":"10.3390\/v12030311"},{"key":"ref_51","unstructured":"Boehringer Ingelheim (2025, September 16). opnMe.com\u2014Boehringer Ingelheim Open Innovation Portal. Available online: https:\/\/www.opnme.com\/molecules\/cdk8-bi-1347."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"9337","DOI":"10.1021\/acs.jmedchem.6b00597","article-title":"Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening","volume":"59","author":"Czodrowski","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1021\/acs.jmedchem.5b01685","article-title":"Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19","volume":"59","author":"Mallinger","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Hahn, F., H\u00e4ge, S., Herrmann, A., Wangen, C., Kicuntod, J., Jungnickl, D., Tillmanns, J., M\u00fcller, R., Fraedrich, K., and \u00dcberla, K. (2021). Methodological Development of a Multi-Readout Assay for the Assessment of Antiviral Drugs against SARS-CoV-2. Pathogens, 10.","DOI":"10.3390\/pathogens10091076"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"106168","DOI":"10.1016\/j.antiviral.2025.106168","article-title":"The conserved core nuclear egress complex (NEC) as an antiherpesviral drug target: Pharmacophore-based identification of NEC-specific inhibitors","volume":"239","author":"Tillmanns","year":"2025","journal-title":"Antivir. Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"001556","DOI":"10.1099\/jgv.0.001556","article-title":"Equine herpesvirus 1 elicits a strong pro-inflammatory response in the brain of mice","volume":"102","author":"Mesquita","year":"2021","journal-title":"J. Gen. Virol."},{"key":"#cr-split#-ref_57.1","unstructured":"EFSA Panel on Animal Health and Welfare (AHAW), Nielsen, S.S., Alvarez, J., Bicout, D.J., Calistri, P., Canali, E., Drewe, J.A., Garin-Bastuji, B., Gonzales Rojas, J.L., and Gort\u00e1zar, C. (2022). Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation"},{"key":"#cr-split#-ref_57.2","unstructured":"(EU) No 2016\/429): Infection with Equine Herpesvirus-1. EFSA J., 20, e07036."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Tillmanns, J., Kicuntod, J., Ehring, A., Elbasani, E., Borst, E.M., Obergf\u00e4ll, D., M\u00fcller, R., Hahn, F., and Marschall, M. (2024). Establishment of a Luciferase-Based Reporter System to Study Aspects of Human Cytomegalovirus Infection, Replication Characteristics, and Antiviral Drug Efficacy. Pathogens, 13.","DOI":"10.3390\/pathogens13080645"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"104861","DOI":"10.1016\/j.antiviral.2020.104861","article-title":"Target verification of artesunate-related antiviral drugs: Assessing the role of mitochondrial and regulatory proteins by click chemistry and fluorescence labeling","volume":"180","author":"Hahn","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_61","unstructured":"Kazuhiro, O. (2025). Addgene Plasmid # 72486, Baylor College of Medicine."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1128\/AAC.46.4.991-995.2002","article-title":"Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir","volume":"46","author":"Kern","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1006\/viro.2002.1488","article-title":"The equine herpesvirus 1 UL34 gene product is involved in an early step in virus egress and can be efficiently replaced by a UL34-GFP fusion protein","volume":"300","author":"Neubauer","year":"2002","journal-title":"Virology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e00473-17","DOI":"10.1128\/JVI.00437-17","article-title":"Cell Culture Systems to Study Human Herpesvirus 6A\/B Chromosomal Integration","volume":"91","author":"Gravel","year":"2017","journal-title":"J. Virol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1128\/AAC.44.6.1588-1597.2000","article-title":"Recombinant green fluorescent protein-expressing human cytomegalovirus as a tool for screening antiviral agents","volume":"44","author":"Marschall","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jviromet.2011.03.005","article-title":"A reporter system for Epstein-Barr virus (EBV) lytic replication: Anti-EBV activity of the broad anti-herpesviral drug artesunate","volume":"173","author":"Auerochs","year":"2011","journal-title":"J. Virol. Methods"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"113909","DOI":"10.1016\/j.jviromet.2020.113909","article-title":"A quantitative nuclear egress assay to investigate the nucleocytoplasmic capsid release of human cytomegalovirus","volume":"283","author":"Horsch","year":"2020","journal-title":"J. Virol. Methods"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"L\u00f6sing, J., H\u00e4ge, S., Sch\u00fctz, M., Wagner, S., Wardin, J., Sticht, H., and Marschall, M. (2022). \u2018Shared-Hook\u2019 and \u2018Changed-Hook\u2019 Binding Activities of Herpesviral Core Nuclear Egress Complexes Identified by Random Mutagenesis. Cells, 11.","DOI":"10.3390\/cells11244030"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1099\/jgv.0.000337","article-title":"New insight into the phosphorylation-regulated intranuclear localization of human cytomegalovirus pUL69 mediated by cyclin-dependent kinases (CDKs) and viral CDK orthologue pUL97","volume":"97","author":"Graf","year":"2016","journal-title":"J. Gen. Virol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1099\/jgv.0.000939","article-title":"Dynamic regulatory interaction between cytomegalovirus major tegument protein pp65 and protein kinase pUL97 in intracellular compartments, dense bodies and virions","volume":"98","author":"Buscher","year":"2017","journal-title":"J. Gen. Virol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Steingruber, M., and Marschall, M. (2020). The Cytomegalovirus Protein Kinase pUL97:Host Interactions, Regulatory Mechanisms and Antiviral Drug Targeting. Microorganisms, 8.","DOI":"10.3390\/microorganisms8040515"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/10\/1560\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T04:13:44Z","timestamp":1760760824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/10\/1560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":72,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["ph18101560"],"URL":"https:\/\/doi.org\/10.3390\/ph18101560","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]}}}